Use of combination of SMYD3-shcbp1 inhibitor and PD1 inhibitor in preparation of drug for treating cancer

Through the combined use of SMYD3 inhibitor or SHCBP1 inhibitor and PD1 inhibitor, the SMYD3-SHCBP1 signaling pathway is inhibited, and the problem of resistance to PD1 antibody treatment in breast cancer is solved, significantly inhibiting tumor progression and enhancing the therapeutic effect.

WO2024230093A1PCT designated stage expired Publication Date: 2024-11-14UNIV OF MACAU
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/128705
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-06
Filing Date
2023-10-31
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Breast cancer is resistant to PD1 antibody treatment, and the prior art is difficult to effectively inhibit the tumor immunosuppressive microenvironment caused by the SMYD3-SHCBP1 signaling pathway, resulting in poor treatment effect.

Method used

Using SMYD3 inhibitors or SHCBP1 inhibitors, such as trametinib, combined with PD1 inhibitors, reduces drug resistance of cancer cells and enhances the function of immune cells, making tumors sensitive to PD1 antibody treatment by inhibiting the SMYD3-SHCBP1 signaling pathway. .

Benefits of technology

It significantly inhibits the progression of breast tumors, reduces drug resistance of cancer cells, enhances the response to PD1 antibody treatment, provides new treatment strategies, and improves the therapeutic effect of breast cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023128705_14112024_PF_FP_ABST
    Figure CN2023128705_14112024_PF_FP_ABST
Patent Text Reader

Abstract

A use of a SMYD3-SHCBP1 inhibitor in combination with a PD1 inhibitor in preparation of a drug for treating cancer. It is determined via experiments that Smyd3-Shcbp1 acts as an initial tumorigenic signal that mediates the tumorigenic effects of Brca1 and ERα during pregnancy, before and during tumorigenesis in precancerous mammary epithelial cells. Moreover, it is proved that elevated Smyd3-Shcbp1 signaling can reprogram a tumor immunosuppressive microenvironment, and immunotherapeutic drug resistance develops after PD1 antibody treatment. Treatment with trametinib can reverse the expression of SMYD3-SHCBP1, the function of effector T cells can be enhanced by treatment using trametinib and a PD1 antibody in combination, and breast tumor with elevated SMYD3 and SHCBP1 are sensitive to ICB. The understanding of breast tumor progression is improved, and a new selection strategy is provided for breast cancer patients.
Need to check novelty before this filing date? Find Prior Art

Description

Application of SMYD3-SHCBP1 inhibitor and PD1 inhibitor in combination in the preparation of cancer treatment drugs

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This disclosure claims priority to Chinese patent application No. 2023105056286, filed with the State Intellectual Property Office of China on May 6, 2023, entitled “Application of a combination of SMYD3-SHCBP1 inhibitors and PD1 inhibitors in the preparation of drugs for treating cancer,” the entire contents of which are incorporated herein by reference. Technical Field

[0003] The present disclosure relates to the technical field of cancer treatment, and in particular, to the use of a SMYD3-SHCBP1 inhibitor in combination with a PD1 inhibitor in the preparation of a drug for treating cancer. Background Art

[0004] Breast cancer has the highest incidence of all cancers, with 2.26 million new cases and 68,500 deaths worldwide in 2020. Over 90% of breast cancers develop without a clear etiology, while 5–10% are heritable and are associated with germline mutations in several cancer susceptibility genes, primarily breast cancer-associated 1 and 2 (BRCA1 / 2). Furthermore, approximately 0.2–3.8% of breast cancer cases are pregnancy-associated breast cancer (PABC), which occurs during pregnancy or within 12 months postpartum. PABC is diagnosed in approximately 1 in 3,000 pregnancies, but its incidence is likely to increase with the increasing age at first full-term birth. Furthermore, the one-year PABC threshold is not a universally accepted definition, as the effects of pregnancy on breast cancer can be profound even after one year postpartum and persist for several years. PABC has a more aggressive clinical course and a higher mortality rate than other forms of breast malignancy. The development of PABC is associated with multiple factors, including family history and BRCA1 / 2 mutations, immune regulation, age at first pregnancy, breastfeeding method, breast involution, and the levels of some marker genes, such as estrogen receptor α (ERα), transforming growth factor β (TGF-β), and matrix metalloproteinases (MMPs).

[0005] BRCA1 is a well-known tumor suppressor that plays a crucial role in numerous important biological processes, including DNA damage repair, the cell cycle, centrosome amplification, DNA replication, chromatin remodeling, protein ubiquitination, and the tumor microenvironment. BRCA1 expression is low but detectable in mammary epithelial cells of breast tissue. Its expression is induced and rapidly increases during early pregnancy, remaining high during mid-pregnancy when mammary epithelial cells are in a state of rapid proliferation. Subsequently, its expression gradually decreases during the later stages of mammary epithelial differentiation. This expression pattern is similar to that of ERα, which plays a crucial role in BRCA1-associated breast cancer and extensively interacts with BRCA1 signaling during pregnancy and other stages of mammary gland development and maintenance. In humans, 71.4% of BRCA1-associated breast cancers are ERα-positive at stage 1, but the proportion of ERα-positive breast cancers decreases to 41.7% and 15.7% at stages 2 and 3, respectively.

[0006] Summary of the Invention

[0007] The present disclosure provides use of a SMYD3 inhibitor and / or an SHCBP1 inhibitor in the preparation of a medicament for preventing or treating cancer.

[0008] Optionally, the cancer is a solid tumor.

[0009] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0010] Optionally, the solid tumor is a cancer selected from the group consisting of breast cancer, melanoma, lung cancer, or liver cancer.

[0011] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121.

[0012] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib.

[0013] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor inhibits the expression of Smyd3 or Shcbp1, thereby inhibiting the abnormal activation of SMYD3 / SHCBP1 and its downstream signaling pathways in cancer and the formation of a tumor immunosuppressive microenvironment.

[0014] The present disclosure provides a use of a SMYD3 inhibitor and / or an SHCBP1 inhibitor in the preparation of a medicament for reducing the drug resistance of cancer cells.

[0015] Optionally, the cancer cells are tumor cells or cancer cells that are insensitive to PD1 antibody treatment.

[0016] Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

[0017] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121;

[0018] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib.

[0019] The present disclosure also provides a use of a SMYD3 inhibitor and / or an SHCBP1 inhibitor in combination with a PD1 inhibitor in the preparation of a drug for preventing or treating cancer.

[0020] Optionally, the cancer is a solid tumor.

[0021] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0022] Optionally, the solid tumor is a cancer selected from the group consisting of breast cancer, melanoma, lung cancer, or liver cancer.

[0023] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121.

[0024] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib.

[0025] Optionally, the PD1 inhibitor is an anti-PD1 antibody.

[0026] Optionally, the anti-PD1 antibody is selected from at least one of the following groups: Nivolumab, Pembrolizumab, Pidilizumab, Lambrolizumab, BMS-936559, Atezolizumab, AMP-224, AMP224, AUNP12, BGB108, MCLA134, MEDI0680, PDROOl, REGN2810, SHR1210, STIA110X, STIA1110, TSR042, BMS-936558, BGB-A317, BCD-100 and JS001.

[0027] The present disclosure provides a medicine or a pharmaceutical composition, wherein the active ingredients of the medicine include: a SMYD3 inhibitor and / or an SHCBP1 inhibitor.

[0028] Optionally, the active ingredient of the drug also includes: PD-1 inhibitor.

[0029] Optionally, the drug further comprises pharmaceutically acceptable excipients.

[0030] The present disclosure also provides a method for preventing or treating tumors, comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or an SHCBP1 inhibitor to a subject in need thereof.

[0031] Optionally, the tumor is a solid tumor.

[0032] Optionally, the solid tumor is a benign tumor or a malignant tumor.

[0033] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0034] Optionally, the benign tumor is a breast tumor.

[0035] The present disclosure also provides a method for inhibiting, reversing or reducing the drug resistance of drug-resistant cancer cells, comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or an SHCBP1 inhibitor to a subject in need thereof.

[0036] Optionally, the cancer cells are tumor cells or cancer cells that are insensitive to PD1 antibody treatment.

[0037] Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

[0038] The present disclosure also provides a method for preventing or treating tumors, comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or an SHCBP1 inhibitor and a PD1 inhibitor to a subject in need thereof.

[0039] Optionally, the tumor is a solid tumor.

[0040] Optionally, the solid tumor is a benign tumor or a malignant tumor.

[0041] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0042] Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor and PD1 inhibitor are administered concurrently or sequentially.

[0043] Optionally, the benign tumor is a breast tumor.

[0044] The present disclosure also provides a SMYD3 inhibitor and / or an SHCBP1 inhibitor for use in preventing or treating tumors.

[0045] Optionally, the tumor is a solid tumor.

[0046] Optionally, the solid tumor is a benign tumor or a malignant tumor.

[0047] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0048] Optionally, the benign tumor is a breast tumor.

[0049] The present disclosure also provides a SMYD3 inhibitor and / or SHCBP1 inhibitor for inhibiting, reversing or reducing the drug resistance of drug-resistant cancer cells.

[0050] Optionally, the cancer cells are tumor cells or cancer cells that are insensitive to PD1 antibody treatment.

[0051] Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

[0052] The present disclosure also provides a SMYD3 inhibitor and / or SHCBP1 inhibitor combined with a PD1 inhibitor for use in preventing or treating tumors.

[0053] Optionally, the tumor is a solid tumor.

[0054] Optionally, the solid tumor is a benign tumor or a malignant tumor.

[0055] Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment.

[0056] Optionally, the benign tumor is a breast tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0057] In order to more clearly illustrate the technical solutions of the embodiments of the present disclosure, the following briefly introduces the drawings required for use in the embodiments. It should be understood that the following drawings only illustrate certain embodiments of the present disclosure and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other relevant drawings can be obtained based on these drawings without paying any creative work.

[0058] FIG1 is a schematic diagram of transcriptional abnormalities associated with open chromatin in Brca1-MT mice on gestational day 12 in Example 1;

[0059] FIG2 is a schematic diagram showing elevated genome-wide gene expression in Brca1-MT mice on gestational day 12 in Example 1;

[0060] FIG3 is a schematic diagram showing that Smyd3 is upregulated in both Brca1-MT mice and human breast cancer tissues in Example 2;

[0061] FIG4 is a schematic diagram showing the increased expression level of SMYD3 in different types of breast cancer in Example 2;

[0062] FIG5 is a schematic diagram showing that Smyd3 is negatively regulated by Brca1 and positively regulated by ERα during the occurrence and development of breast tumors in Example 3;

[0063] FIG6 is a schematic diagram of ERα-positive enhanced oncogenic signaling in Example 3;

[0064] FIG7 is a schematic diagram showing that Smyd3 enhances the activation of oncogenes and oncogenic pathways in Example 4;

[0065] FIG8 is a schematic diagram showing the elevated expression of oncogenes induced by Smyd3 in Example 4;

[0066] FIG9 is a schematic diagram showing that inhibiting the expression of SMYD3 and SHCBP1 reduces the activity of oncogenic pathways in Example 5;

[0067] FIG10 is a schematic diagram showing that inhibition of oncogenic signaling of SMYD3 or SHCBP1 reverses the splenomegaly phenotype in Example 5;

[0068] Figure 11 is a schematic diagram showing the increase of SMYD3 and SHCBP1, accumulation of MDSCs, and decrease in the number of T cells in breast tissue in Example 6;

[0069] Figure 12 is a schematic diagram showing a decrease in M1-like macrophages and an increase in M2-like macrophages in HP-OE-Smyd3 mice in Example 6;

[0070] Figure 13 is a schematic diagram showing that the combination of PD1 antibody and trametinib can reduce breast tumor progression and increase the number of effector T cells in Example 7;

[0071] FIG14 is a schematic diagram showing that trametinib reverses the oncogenic expression of Smyd3 and Shcbp1 in breast epithelial cells in Example 7. DETAILED DESCRIPTION

[0072] Reference will now be made in detail to embodiments of the present disclosure, one or more examples of which are described below. Each example is provided to illustrate, not to limit, the present disclosure. Indeed, it will be apparent to those skilled in the art that various modifications and variations may be made to the present disclosure without departing from the scope or spirit of the present disclosure. For example, features illustrated or described as part of one embodiment may be used in another embodiment to produce further embodiments.

[0073] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the preparations or unit doses herein, some methods and materials are now described. Unless otherwise indicated, the techniques employed or contemplated herein are standard methods. Materials, methods, and examples are illustrative and non-limiting only.

[0074] The purpose of the present disclosure is to provide a use of a SMYD3-SHCBP1 inhibitor and a PD1 inhibitor in combination for the preparation of a drug for treating cancer, which improves the understanding of breast tumor progression and provides a new selection strategy for breast cancer patients.

[0075] The present disclosure is achieved as follows:

[0076] Through studies in BRCA1 mutant mouse models and human breast cancer, the inventors discovered that BRCA1 deficiency upregulates Smyd3-Shcbp1 signaling, leading to an open chromatin structure characterized by high H3K4me3 expression and low H3K9me3 expression, and activating the Ras-MAPK oncogenic pathway in pre-malignant breast cancer epithelial cells. Smyd3-Shcbp1 signaling is exacerbated by estrogen-estrogen receptor (ERα) in pre-malignant breast cancer epithelial cells, forming a tumor immunosuppressive microenvironment (TIME) and enhancing tumor growth associated with resistance to PD-1 antibody immunotherapy. Based on these studies, the inventors identified SMYD3-SHCBP1 as a therapeutic target to inhibit cancer progression.

[0077] Smyd3 is a histone methyltransferase that specifically methylates the Lys-4 site of histone H3, inducing dimethylation and trimethylation (H3K4me2 and H3K4me3), but not monomethylation (H3K4me1). Smyd3 is known to be highly expressed in various human cancers. In this disclosure, the inventors experimentally demonstrate that upregulated SMYD3 may be enhanced by ERα, acting as an oncogenic initiation factor for Brca1-MT cell growth, and demonstrate that ERα and Smyd3 signaling promote the development and progression of breast tumors.

[0078] The Src homology 2 domain containing (Shc) family comprises four subgene families: ShcA, ShcB, ShcC, and ShcD. SHC SH2-domain binding protein 1 (Shcbp1) was first identified in yeast two-hybrid assays to identify novel binding partners for the adaptor protein ShcA. Because Shcbp1 is upregulated upon T cell activation, it was originally named murine activated lymphocyte protein (mPAL). Shcbp1 can influence the growth of various malignancies, such as hepatocellular carcinoma, glioma, and synovial sarcoma, through other pathways. It is also considered one of four marker genes that predict breast cancer survival, metastasis, and drug response. When further exploring the regulatory factors or pathways of the carcinogenic effects of ERα and Smyd3 caused by Brca1 deficiency, the inventors found that Smyd3 can directly regulate the expression of Shcbp1, and then proved that Smyd3 can positively induce the increased expression of Shcbp1 and Kras-MAPK signals, continuously maintain the expression of Shcbp1 and Kras-MAPK signals, and promote the progression of breast tumors.

[0079] Furthermore, the inventors demonstrated that Smyd3 and Shcbp1 are major oncogenic drivers, and that silencing Smyd3 and Shcbp1 in mammary epithelial cells not only minimizes tumor cell growth but also blocks their negative impact on abnormal immune responses in spleen tissue. Furthermore, when the functions of SMYD3 and SHCBP1 are disrupted, the progression of breast tumors can be significantly inhibited.

[0080] Since Smyd3-Shcbp1 serves as the initial tumorigenic signal in precancerous mammary epithelial cells that mediates the tumorigenic effects of Brca1 and ERα during pregnancy, before and during tumor development, inhibiting or silencing the expression of SMYD3-SHCBP1 can weaken the carcinogenic effect of the Kras-MAPK pathway, thereby inhibiting breast tumor formation and slowing breast tumor growth, thereby achieving the purpose of preventing or treating breast cancer.

[0081] After identifying SMYD3-SHCBP1 as a therapeutic target for inhibiting cancer progression, the inventors first used the only known chemical inhibitor, BCI-121, to test its effect on mouse mammary tumor formation. However, the experimental results showed that while it was highly effective in tumor slice cultures, for unknown reasons, it had no significant effect on mouse tumor growth. After extensive and inventive work, the inventors discovered that treatment with trametinib reversed SMYD3-SHCBP1 expression and significantly inhibited it.

[0082] Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK 1 / 2). It primarily inhibits the MAPK pathway by affecting MEK protein, an upstream regulator of the extracellular signal-related kinase (ERK) pathway, thereby inhibiting cell proliferation. Therefore, trametinib is commonly used to treat unresectable or metastatic melanoma with BRAF (murine sarcoma viral oncogene B1 gene) V600E or V600K mutations. This disclosure demonstrates its use for the first time to reverse SMYD3-SHCBP1 expression, thereby preventing or treating breast cancer.

[0083] Since the inventors found that elevated Smyd3 would increase the number of PD1 and CD3 double-positive cells, PD1 antibodies were used for treatment. However, the results showed that PD1 antibody treatment had no significant effect, indicating that breast tumors with elevated Smyd3 and Shcbp1 levels are resistant to PD1 antibody treatment. Blocking the carcinogenic pathway with trametinib can significantly sensitize the immune cell population by reducing stimulation from malignant epithelial cells and blocking the PD1 and PD-L1 interaction between malignant epithelial cells and immune cells caused by elevated Smyd3 and Shcbp1 signals, thereby making the tumor sensitive to PD1 antibody treatment.

[0084] In the present disclosure, the SMYD3 inhibitor or SHCBP1 inhibitor - trametinib and the PD1 inhibitor have a synergistic effect.

[0085] Experimental studies have shown that the SMYD3-SHCBP1 inhibitor trametinib, combined with a PD-1 antibody, can reverse the tumorigenic expression of Smyd3 and Shcbp1 in breast epithelial cells and increase the population of functional T cells, sensitizing breast tumors with high levels of Smyd3 and Shcbp1 to ICB. Trametinib not only reduces breast cancer cells' resistance to PD-1 antibodies but also has a stronger effect on tumor size and weight when combined with PD-1 antibodies.

[0086] In some optional embodiments, the solid tumors disclosed herein include but are not limited to:

[0087] Squamous cell carcinoma, non-small cell lung cancer, squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, glioma, gastrointestinal cancer, kidney cancer, ovarian cancer, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, neuroblastoma, glioblastoma, stomach cancer, bladder cancer, liver cancer, colon cancer, head and neck cancer, gastric cancer, germ cell tumor, pediatric sarcoma, sinonasal natural killer cancer, melanoma, skin cancer, bone cancer, cervical cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervix carcinoma, vaginal cancer, vulvar cancer, cancer of the anal region, testicular cancer, esophageal cancer, small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, ureteral cancer, penile cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphoma, tumor angiogenesis, spinal tumors, brain cancer, brain stem glioma, pituitary adenoma, Kaposi sarcoma, epidermoid carcinoma, squamous cell carcinoma, solid tumors of childhood, environmentally induced cancers, virus-related cancers, and cancers of viral origin.

[0088] In existing mouse models (Brca1Co / Co; MMTV-Cre) generated using the Cre-LoxP method, which carries a mammary-specific Brca1 knockout, nearly all detectable breast tumors are ERα-positive at early stages, with a gradual loss of ERα expression in later stages, suggesting that ERα plays an active role in cancer initiation. Similarly, ovariectomy reduces estrogen production in human BRCA1 mutation carriers and mice with mammary-specific BRCA1 mutations, significantly reducing the frequency of breast cancer formation. Tamoxifen, which blocks E2 / ERα signaling, also reduces cancer risk.

[0089] Previous experiments have identified a downstream gene that links estrogen signaling and the massive upregulation of gene expression during pregnancy. This gene has been further confirmed as a promoter of the oncogenic growth of precancerous cells with Brca1 mutations, and its potential as a therapeutic target for inhibiting cancer progression has been validated. However, the specific therapeutic approach under which this target can be effective in treating breast cancer remains to be determined.

[0090] The present disclosure experimentally identified Smyd3-Shcbp1 as the initial tumorigenic signal in precancerous mammary epithelial cells that mediates the tumorigenic effects of Brca1 and ERα during pregnancy, before tumor development, and during tumor development. It also demonstrated that elevated Smyd3-Shcbp1 signals can reprogram the tumor immunosuppressive microenvironment (TIME) and produce immunotherapy resistance after PD1 antibody treatment. Treatment with trametinib reversed the expression of SMYD3-SHCBP1, and combined trametinib and PD1 antibody therapy enhanced the function of effector T cells, making breast tumors with elevated SMYD3 and SHCBP1 sensitive to ICB. This disclosure improves our understanding of breast tumor progression and provides a new selection strategy for breast cancer patients.

[0091] Based on the above studies, practice of the present disclosure will employ, unless otherwise indicated, conventional techniques of cell biology, molecular biology (including recombinant techniques), microbiology, biochemistry, and immunology, which are within the capabilities of a person skilled in the art. The technique is fully explained in the literature, for example, in Molecular Cloning: A Laboratory Manual, 2nd ed. (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Handbook of Experimental Immunology (DM Weir and CC Blackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JM Miller and MP Calos, eds., 1987); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987); and PCR: The Polymerase Chain Reaction. Reaction" (Mullis et al., eds., 1994); and Current Protocols in Immunology (JE Coligan et al., eds., 1991), each of which is expressly incorporated herein by reference.

[0092] To make the purpose, technical solutions, and advantages of the embodiments of the present disclosure more clear, the technical solutions in the embodiments of the present disclosure are described clearly and completely below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall be followed. Where the manufacturer of the reagents or instruments used is not specified, all are commercially available conventional products.

[0093] Example

[0094] The features and performance of the present disclosure are further described in detail below with reference to the embodiments.

[0095] Experimental materials and methods used in the examples

[0096] Mouse model

[0097] All experimental animals and protocols were provided by the Animal Experimentation Center of the University of Macau. Survival curves and tumor growth were observed in female mice with a whole-body exon 11 deletion of Brca1 accompanied by rescue of the p53+ / - mutation (Brca1Δ / Δ; p53+ / -) and Brca1 double-heterozygous female mice (Brca1Δ / +; p53+ / -) after two pregnancies or during the nulliparous period. Mammary glands of wild-type and Brca1 mutant mice were isolated from 3XFlag-Brca1+ / + and Brca1 conditional knockout mice (Brca1co / coTrp53+ / -MMTV-Cre mice) at gestational day 12.5 (P12) for chromatin immunoprecipitation (ChIP) analysis. In xenograft studies, 6-week-old female nude mice were implanted with B477 or G600 (2×105 cells), MDA-MB-231 (2×106 cells), or HCC1937 (5×106 cells) via mammary fat pad (MFP) injection. LMBG (545) (5×106 cells) and HP5712 (1×106 cells) were injected into FVB female mice via MFP injection. In the xenograft model, 6-week-old female nude mice were implanted with cells via the fat pad after fertilization. In the drug-treated mouse model, PD-1 antibody was diluted in PBS and injected intraperitoneally three times at 0.1 mg / mouse. Trametinib (Sellectchem, USA, Cat No. S2673) was dissolved in 4% DMSO and corn oil and then mixed with 0.5% hydroxypropyl methylcellulose (HPMC, Sigma, USA) and 0.2% Tween-80. Mice were gavaged every other day (0.5 mg / kg).

[0098] Cell culture and lentiviral infection

[0099] B477 (WT wild-type mammary epithelial cell line) and G600 (Brca1 mutant mammary epithelial cell line) cells were derived from the mammary glands of WT and Brca1 mutant mice, respectively. The 545 and HP5712 cell lines were derived from the FVB mouse mammary tumor model. HEK293T, MDA-MB-231, and HCC1937 cell lines were obtained from ATCC. All cell lines were grown in DMEM (Life Technologies, Carlsbad, CA) supplemented with 10% (v / v) fetal bovine serum (FBS) (Sigma, St. Louis, MO), 1% l-glutamine (Life Technologies), 0.6% Pen-Strep (Life Technologies), and 10 μg / ml insulin (Invitrogen, Carlsbad, CA). For lentiviral infection, different sgRNA sequences were cloned into the V2 vector (Addgene plasmid No. 52961) using a universal method. 293T cells were seeded on 10 cm culture dishes and transfected with psPAX2 (3 μg), pMD2.G (9 μg), and lentiCRISPRV2 plasmids (12 μg). Lentivirus-containing supernatant was collected 48 hours after transfection and filtered through a 0.45-μm filter (Corning, NY). Transfected cells were selected with puromycin 72 hours later.

[0100] Microarray and Gene Set Enrichment Analysis (GSEA)

[0101] Gene fragments were extracted from the 4499-gene table of the Gene Expression Omnibus (GEO) database with accession number GSE92342, and gene fragment enrichment analysis (GSEA) was performed from the 6331-gene table of the Morpheus-Broad Institute (https: / / software.broadinstitute.org).

[0102] Chromatin immunoprecipitation (ChIP) analysis

[0103] Fresh mouse mammary glands were extracted from nulliparous and 12-day pregnant mice, cut into pieces, and digested at 37°C for approximately 3 hours. Approximately 2.0×107 freshly isolated mouse mammary epithelial cells were then used for ChIP. Single-cell suspensions were cross-linked with 1% (v / v) formaldehyde solution at room temperature for 5 minutes, and the reaction was terminated with glycine buffer. Chromatin was then sonicated using the truChIP Ultra-Low Chromatin Shearing Kit (Covaris, USA, 520154). Chromatin DNA was immunoprecipitated using antibodies against Brca1 and ERα, as well as antibodies against the histone marks H3K4me3 and H3K27Ac, ​​using the LowCell ChIP Kit™ (Diagenode, Japan, Cat Nos. C01010072, C01010073). DNA libraries were prepared using the TruSeq ChIP Sample Prep Kit (Illumina, USA, 15034288, 15034289). Mouse and rabbit IgG were used as negative controls, and the results were normalized to the input. The ChIP DNA libraries were then mixed and sent for sequencing. The quality of the raw data was checked using the FastQC program. The raw reads were aligned to the mouse reference genome GRCm38.84 using bowtie2 software. The alignment output of bowtie2 was converted to BAM format using the samtools software suite. For ChIPseq data visualization, mapped reads were extended to 200 bp in the 5'->3' direction using the 'macs2 pileup' command and to 1 million using the 'macs2 bdgopt' command in the macs2 tools. UCSC Kent converted the genome coverage files from BedGraph to BigWig format using the 'bedSort' and 'bedGraphToBigWig' programs. These ChIPseq genome coverage files were visualized using the Integrative Genomics Viewer software.

[0104] Bond strength analysis

[0105] The general binding strength analysis of the promoter region was performed using the "deeptools" software (https: / / deeptools.readthedocs.io / en / develop / index.html).

[0106] ChIP-qPCR and qRT-PCR analysis

[0107] In ChIP-qPCR, immunoprecipitated chromatin DNA from mouse mammary tissue was amplified by qPCR using primers targeting Brca1 or ERα. Immunoprecipitated chromatin DNA from B477 and G600 cells was amplified by qPCR using primers targeting Shcbp1. Total RNA was isolated from tumors, fresh mouse mammary glands, or cell lines using TRIzol reagent (Thermo Fisher Scientific, USA) for qRT-PCR analysis and reverse transcribed using a quantitative reverse transcription kit (Qiagen, Germany, 205313). RT-PCR was performed using FastStart Universal SYBR Green Master Mix (Roche, Swiss, 24759100) in QuantStudio TM Reactions were performed in a 7Flex Real-Time PCR System (Thermo Fisher Scientific, USA). Relative quantification was assessed using 18S normalization.

[0108] Protein extraction and western blotting (WB) analysis

[0109] Tumor, breast tissue, and cells were washed with PBS and then solubilized with RIPA buffer (50 mM Tris-HCl (pH 7.4), 1% NP-40, 150 mM NaCl, 0.1% SDS, 1% deoxycholic acid, 1 mM EDTA, and 10% glycerol) supplemented with protease inhibitors (Roche, Switzerland, 04693159001) and phosphatase inhibitors (Roche, Switzerland, 04906837001). Western blotting was performed using the ODYSSEY CLx system (LI-COR) and corresponding antibodies. Band intensities were quantified using ImageJ (NIH, MD, USA). Relative quantification was obtained by normalization to β-actin protein.

[0110] H&E, immunohistochemistry (IHC), and immunofluorescence (IF) staining

[0111] Tumor or breast tissue was fixed with 4% v / v formaldehyde and embedded in paraffin. Paraffin sections were then dewaxed and dehydrated with xylene and graded ethanol. Dewaxed sections were boiled in 10 ml of 10× R-Buffer-A (Electron Microscopy Sciences, Cat No. 62706-10) in 90 ml of dH2O and stained with the corresponding antibodies according to standard methods. Images were acquired using an Olympus IX83 inverted microscope (Olympus Corp., Japan) or a Nikon A1R confocal system (Nikon Corp., Japan). Fluorescence signals and DAB intensity were analyzed using ImageJ (NIH, MD, USA).

[0112] Transfection and luciferase reporter assay

[0113] One day before transfection, cells were seeded in 24-well plates and transfected with 0.8 μg of plasmid using Lipofectamine™ 3000 (Thermo Fisher Scientific, USA, L3000015) according to the manufacturer's instructions. Cells were cultured for 24 hours after transfection and then treated with 100 nM 17β-estradiol (Sigma, USA) for 24 hours. Luciferase activity was assessed using the Dual-Luciferase Reporter System (Promega, USA, E1960). Results were normalized to Renilla luciferase activity.

[0114] Cell proliferation assay

[0115] Cells (3000 per well) were seeded into 96-well plates and then The cells were cultured and observed in a live cell analysis system for one week, and then a cell proliferation curve was generated.

[0116] Tumor slice culture

[0117] Fresh tumor tissue was trimmed into an appropriate size of 250 μm and then embedded in a recombinant collagen gel consisting of three solutions. The formula is as follows: A: 3D culture matrix type 1 collagen (R&D Systems, Minneapolis, USA). Solution B: Ham's F-12 nutrient mix powder (Gibco TMConcentrated sterile culture medium (10×) consisting of 1% A (1% IL-17, ... The SMYD3 inhibitor BCI-121 (Chemicals, Shanghai, China, DC10885) was dissolved in DMSO to prepare a stock solution and stored at -80°C before use. BCI-121 was diluted with culture medium to 50 μM, 100 μM, 200 μM, or 300 μM before use.

[0118] Mass Cytometry (CyTOF)

[0119] Mouse mammary gland and breast tumor tissues were minced into small pieces and digested at 37°C for approximately 1 hour. Single cells were collected through a 40 μm cell strainer, washed with HBSS, and resuspended in prewarmed serum-free medium. 1×107 single cells were mixed with 10 μM cisplatin working solution and incubated at room temperature for 5 min. Then, the cells were washed with Maxpar cell staining buffer and 1-3×106 cells were incubated with antibodies (CD45-147Sm: DVS-Fluidigm, Catalog 3147003B; CD3e-152Sm: DVS-Fluidigm, Catalog 3152004B; CD4-145Nd: DVS-Fluidigm, Catalog 3145002B; CD8a-146Nd: DVS-Fluidigm, Catalog 3146003B; Ly6G-141Pr: DVS-Fluidigm, Catalog 3141008B; Ly6C-162Dy: DVS-Fluidigm, Catalog Antibody-stained cells were then mixed with Cell-ID Intercalator-Ir solution diluted in Maxpar Fix and Perm Buffer and incubated overnight at 4°C. After rinsing with Maxpar cell staining buffer and Maxpar water, 2.5–5 × 10⁵ / ml of cells were diluted in EQ™ Four Element Calibration Buffer (Cat. #201078). Data were acquired on a CyTOF2 System Mass Cytometer (Fluidigm Helios). Different cell populations were analyzed using FlowJo 10.4 software, and statistical calculations were performed using GraphPad Prism 9 software.

[0120] Statistical analysis

[0121] Statistical analysis was performed using the Student's t-test or one-way or two-way analysis of variance. A p-value < 0.05 was considered statistically significant and is expressed as p < 0.05*, p < 0.01**, p < 0.001***, and p < 0.0001****. Values ​​are presented as mean ± SD or mean ± SEM. Sample sizes (n) are provided in the corresponding content for individual statistical analyses. Each dataset was analyzed ≥ 3 times to ensure reproducibility.

[0122] Data availability

[0123] The ChIP-seq data generated in this study have been deposited in the National Institute Center for Biotechnology Information Sequence Read Archive database with accession number: PRJNA799920.

[0124] Study Approval

[0125] All mouse strains were maintained at the Animal Experimentation Center of the Faculty of Health Sciences, University of Macau, in accordance with institutional guidelines. All experiments were approved by the Animal Ethics Committee of the Faculty of Health Sciences, University of Macau (Protocol ID: UMARE-AMEND-100).

[0126] Example 1

[0127] This example demonstrates that Brca1-deficient breast tissue exhibits transcriptional abnormalities, open chromatin structure, high expression of H3K4me3, and low expression of H3K9me3.

[0128] Previous studies have demonstrated that Brca1 mutant mammary glands at gestational day 12 are associated with the accumulation of mammary epithelial cells characterized by genomic instability and activation of oncogenic signaling (Figure 1A,B). To identify factors that may initiate cancer growth, a set of experiments was designed to study the mammary glands of wild-type WT and Brca1Co / Co;MMTV-Cre (Brca1-mutant) mice at gestational day 12 (P12) (Figure 1A-B).

[0129] Gene expression profiling analysis showed that pregnancy significantly increased genome-wide gene expression in wild-type pregnant mice at P12 (WTP12) compared with wild-type non-pregnant mice (WTV), and the expression of this subgroup of genes was further elevated in the mammary glands of mutant P12 (MTP12) mice (as shown in Figure 2A).

[0130] The finding of genome-wide upregulation of gene expression in Brca1 mutant mammary tissue prompted the hypothesis that Brca1 deficiency might re-regulate chromatin configuration toward a more "open" character. To test this, immunohistochemistry and IF staining were performed using antibodies against H3K4me3 and H3K9me3. Because H3K4me3 is associated with transcriptional activation and chromatin remodeling, it can be considered a structural marker of more "open" chromatin, while H3K9me3, a more dense chromatin marker, is typically associated with heterochromatin. Consistent with gene expression profiling, more H3K4me3-positive cells were observed in the mammary glands of MTP12 mice than in those of WTP12 mice (Figure 1C). In contrast, fewer H3K9me3-positive cells were observed in the mammary glands of MTP12 mice than in those of WTP12 mice (Figure 1D). To validate this concept, this example performed a gene set enrichment analysis (GSEA) of chromatin remodeling genes expressed in P12. The results showed that 135 genes were enriched in MTP12 breast tissue compared to WTP12 breast tissue, including chromatin remodeling genes (as shown in Figure 1E), chromatin assembly or disassembly genes (as shown in Figure 1F), and chromatin binding genes (as shown in Figure 1G). These experiments indicate that upregulation of gene transcription in Brca1 mutant breast tissue is associated with an "open" chromatin structure in vivo.

[0131] To identify factors that may be negatively regulated by Brca1 but positively regulated by ERα in proliferating mammary epithelial cells, as ERα is the major hormone responsible for mammary epithelial cell proliferation during pregnancy, we used antibodies against H3K4me3, H3K27Ac, ​​Brca1, and ERα to investigate promoter transcriptional activity genome-wide by performing chromatin immunoprecipitation (ChIP) sequencing in primary mammary epithelial cells isolated from MTP12 and WTP12 mice.

[0132] Since Brca1 lacks ChIP-grade antibodies, this example introduces a 3X Flag sequence into the C-terminus of Brca1 before the stop codon in WT embryonic stem cells (ES) (as shown in Figure 1H), and uses Flag-tagged ES cells to generate Brca1-Flag mice. The binding specificity of Flag and ERα antibodies was verified by ChIP-qPCR (as shown in Figures 2B-C). Using ChIP-seq and Flag, ERα, H3K4me3, and H3K27Ac antibodies, the genome-wide binding patterns of these antibodies in WTP12 and MTP12 mouse mammary epithelial cells were detected. Finally, 6290 binding sites for Flag antibodies and 2124 binding sites for ERα antibodies were detected in WTP12 mammary epithelial cells, respectively (as shown in Figure 2D). In MTP12 mammary epithelial cells, although the total number of H3K4me3 binding sites in the active promoter region was slightly lower in MTP12 (18629) than in WTP12 (18821), the number of ERα binding sites increased to 3684, indicating that Brca1 antagonized ERα binding sites (as shown in Figure 2D). The genome-wide binding intensity analysis of H3K4me3 antibodies showed that the binding intensity of the -2Kb to +2Kb region on both sides of the TSS site in the promoter region of MTP12 mice was much higher than that in WTP12 mice (as shown in Figure 1I-J). This conclusion verifies the open chromatin structure and enhanced genome-wide transcriptional activity in the mammary tissue of Brca1-MT mice.

[0133] Analysis of the binding patterns of these four antibodies revealed that the number of binding sites for the two antibodies targeting H3K4me3 / H3K27Ac (primarily marking active promoters) was 11,210 in WTP12 and 10,171 in MTP12. When ERα binding sites were included, the number decreased to 1,673 and 932 in MTP12 and WTP12 cells, respectively (as shown in Figure 1K). This result suggests that ERα can enhance more promoters in Brca1-MT mice. Further, this example investigated how many of these binding sites can also be bound by Brca1 (pulled down by the Flag antibody). The data showed 1,162 and 615 binding sites in MTP12 and WTP12, respectively (as shown in Figure 1K). When the two groups of genes were further compared, 861 new ERα binding sites and 301 original ERα binding sites were found (as shown in Figure 1L), indicating that the activity of ERα in transcriptional regulation is significantly increased in MTP12 mice. Consistent with the above analysis, enhanced binding of ERα and H3K4me3 to promoters, including Esr1, Bard1, Crebbp, Bcas3, Myc, Rel, and Gadd45g (as shown in Figures 1M-O and 2E-H), suggested that more enhanced promoters may be responsible for the abnormal proliferation of Brca1-MT epithelial cells before breast tumor formation.

[0134] Example 2

[0135] This example demonstrates that Smyd3 expression is elevated in both precancerous breast tissue and breast tumor tissue.

[0136] According to the results of Example 1, compared with the WTP12 control, the MTP12 mammary tissue showed increased transcription characterized by an open chromatin structure, so it was further speculated that the genes that trigger these changes may also be the cause of the occurrence and development of breast tumors. To identify these genes, 301 genes with common activated promoters in the mammary gland of WTP12 mice and 861 genes with specific activated promoters in MTP12 mice were first compared using 452 chromatin remodeling genes, and 11 and 14 common genes were identified, respectively (as shown in Figures 3A-B).

[0137] To further narrow the candidate genes, we next compared these genes with 135 genes previously identified based on their expression in WTP12 mammary glands and their increased expression in MTP12 mammary glands. This led to the discovery of Esr1 and Smyd3 (Figure 3C).

[0138] Because Smyd3 is highly expressed in a variety of human cancers and amplified in 24% of breast cancer patients (as shown in Figures 4A-B), this example focused on how Smyd3 exerts its carcinogenic effects during pregnancy. First, it was demonstrated that the expression levels of Smyd3 and its downstream genes (Psmd9 and Psen2) were elevated in the mammary tissue of MTP12 (as shown in Figure 3D). The expression level of the Esr1 gene was also high at different developmental stages of Brca1-MT mammary tissue (as shown in Figure 3E). Next, the expression of Smyd3 was examined in precancerous mammary tissue, aged mammary tissue, and tumor tissue of 4-month-old non-pregnant mice. The data showed that Smyd3 expression was significantly elevated at all stages of Brca1-MT mice (as shown in Figure 3F), indicating that elevated Smyd3 expression may be a carcinogenic initiator before tumor formation. This example also selectively detected the expression of some genes that can be upregulated based on the binding pattern with H3K4me3 observed in the ChIP sequence data, and confirmed their higher expression levels in precancerous and tumor breast tissues (as shown in Figures 4C-D). As shown by Western blots and IHC staining, the protein level of Smyd3 in MTP12 breast and MT tumor tissues was consistent with the transcription level and also showed an increased state compared with the control (as shown in Figures 3G-K). These data indicate that the increase in Smyd3 expression in the mammary gland and breast tumor tissues of Brca1-MT mice can trigger and continue to induce the expression of oncogenes in precancerous tissues and breast tumors.

[0139] To further investigate the causal relationship between SMYD3 upregulation and BRCA1 functional loss in breast cancer patients, immunohistochemical staining with BRCA1 and SMYD3 antibodies was performed on tumor tissues from patients with pregnancy-associated breast cancer (PABC) and non-pregnancy-associated breast cancer (non-PABC). The data showed that higher levels of BRCA1 protein were detected in the nuclei of non-PABC breast cancer tissues than in PABC breast cancer tissues (Figures 3L-M). SMYD3 protein was readily detected in both the nuclei and cytoplasm of all samples, but was more abundant in the nuclei of PABC breast cancer tissues compared to non-PABC breast cancer tissues (Figures 3N-O). This notion was further supported by increased SMYD3 gene expression in all breast cancers, in breast cancer patients with low or no BRCA1 expression in the TCGA dataset (Figures 3P-R), and in invasive lobular, ductal, and medullary breast cancers from the Curtis Breast Cancer Database (Figures 4E-G). These data suggest that upregulated SMYD3 may be enhanced by ERα and serve as an oncogenic initiator for Brca1-MT cell growth.

[0140] Example 3

[0141] This example demonstrates that ERα and Smyd3 signaling promote the development and progression of breast tumors.

[0142] Because mammary glands fail to develop in ERα-knockout mice, ERα plays a crucial role in mammary epithelial proliferation during pregnancy. Since Esr1 expression is elevated in MTP12 mammary tissue, it is inferred that during pregnancy, ERα activity is abnormally enhanced in Brca1-MT mice, potentially stimulating genome-wide oncogenic expression. Furthermore, since Smyd3 may also promote global gene transcriptional activity and its expression is further increased in MTP12 mammary tissue compared to WTP12 mammary tissue, it is speculated that elevated ERα during pregnancy and activation of oncogenic factors or oncogenic pathways mediated by Smyd3 may promote mammary tumor formation.

[0143] To verify this, this example first confirmed that Smyd3 is located in the cytoplasm and nucleus of WT and Brca1-MT cells (as shown in Figures 6A-B). As previously mentioned, Brca1 and ERα can work together to regulate genes involved in the response body. This example then examined Smyd3 gene expression in WT and Brca1-MT cells with or without 17β-estradiol (E2) treatment. The results showed that Smyd3 expression was already high in Brca1-MT cells (as shown in Figure 5A), and its expression increased further after E2 treatment (as shown in Figure 6C). To further verify whether E2-induced Smyd3 elevation increases the expression of its downstream genes, the results showed that after 24 hours of E2 treatment, the expression of known Smyd3 downstream genes Psmd9 and Psen2 (as shown in Figure 5B) as well as the estrogen-related genes Esr1, Pgr, and Ncoa1 (as shown in Figure 5C) was induced, demonstrating that ERα can enhance the expression of Smyd3 and its downstream genes in Brca1-MT mice. Next, this example examined the expression of several candidate genes that may be involved in promoting breast cancer tumorigenesis, including Crebbp, Pcsk6, and Mapk8. It was found that their expression levels were higher in G600 cells than in B477 cells, and further increased after E2 treatment (as shown in Figures 6D-G). This result suggests that due to the loss of Brca1 function, ERα-induced abnormal Smyd3 activity may promote or maintain oncogenic transcription in Brca1-MT cells during and even after pregnancy.

[0144] To further investigate whether Smyd3 expression is regulated by Brca1 and ERα at the transcriptional level, the Smyd3 promoter and a sequence-deleted promoter were cloned into the pGL3 luciferase reporter vector (as shown in Figure 6H ) and luciferase activity was measured under different conditions. The results showed that:

[0145] 1) Deleting the fragment from -250 to the TSS site (MTP5) greatly reduced promoter activity (as shown in Figure 5D), indicating that this fragment is a key region for transcriptional regulation;

[0146] 2) The promoter activity of G600 cells was higher than that of B477 cells, and the promoter activity of G600 cells after E2 treatment was significantly higher than that of B477 cells (as shown in Figure 5E);

[0147] 3) When Brca1 cDNA was introduced into WT and MT mammary epithelial cells, the promoter activity was suppressed in both WT and Brca1-MT cells (as shown in Figure 5E );

[0148] 4) When Brca1 cDNA was expressed in WT and MT cells, promoter activity was still inhibited after E2 treatment (as shown in Figure 5E).

[0149] These data indicate that the Smyd3 promoter can be positively regulated by ERα but also negatively regulated by Brca1, and the effect of ERα on the Smyd3 promoter can be overridden by Brca1.

[0150] Based on the above results, this example uses the following experiment to explore whether the initiation and progression of mammary tumors caused by Brca1 deficiency are affected by pregnancy. First, two groups of nude mice were prepared: non-pregnant mice and nude mice with a single full-term pregnancy. Wild-type WT-B477 cells or mutant Brca1-MT-G600 cells were then implanted into the mammary fat pads of these mice, and tumor growth was monitored. The data showed that there was no significant difference in the growth of tumors formed by WT-B477 cells in the first 17 days (as shown in Figures 5F and H). In contrast, Brca1-MT-G600 cells in pregnant mice grew much faster than those in non-pregnant mice of the same period, although this effect became less obvious in the later stages when the tumors were fully formed (as shown in Figures 5G and H). Western blot (Figure 5I) and IHC staining (Figures 6I-P) showed that the increased levels of ERα, Smyd3, and H3K4me3 proteins in tumors generated by Brca1-MT-G600 cells compared to tumors generated by WT-B477 mice verified the above view.

[0151] This example then further investigated this by using a mouse model of endogenous Brca1 mutation that is homozygous for a germline deletion of full-length Brca1 (D 11) and that dies during intervening pregnancy but survives to adulthood on a p53+ / - mutant background (Brca1 D 11 / D 11 Brca1 D 11 / D 11 ; p53+ / - mice were divided into two groups, one group underwent two complete pregnancy cycles before 4 months of age, and the other group remained non-pregnant. The data showed that the two groups of mice had similar cancer-free survival in the first 35 weeks, after which the tumor development in the non-pregnant group slowed down (as shown in Figure 5J). However, when comparing different tumor types, it was found that about 60% (14 / 23) of the pregnant mice had an increased incidence of mammary tumors, while only 14% (3 / 22) of the non-pregnant mice developed mammary tumors during the same time period (as shown in Figure 5K). In addition, the same number of Brca1 D 11 / D 11 p53+ / - mice (10 / 22 in the nulliparous group and 8 / 23 in the fertile group) also developed other types of cancer, including liver cancer, lymphoma, colon cancer, sarcoma, and salivary gland cancer (as shown in Figure 5K). These data demonstrate that the rapid proliferation of mammary epithelial cells during pregnancy can enrich for Brca1. D 11 / D 11 ; Carcinogens that significantly increase mammary tumor formation in p53+ / - female mice.

[0152] Example 4

[0153] This example demonstrates that Smyd3 enhances Kras / MAPK signaling through the oncogenic effect of Shcbp1.

[0154] The data showed that ERα can stimulate the expression of Smyd3 in conjunction with the loss of Brca1 and promote the growth of breast tumors in Brca1-MT cells. In order to further understand the regulatory factors or pathways of the carcinogenic effects of ERα and Smyd3 caused by Brca1 loss. In this example, 1265 genes were analyzed by KEGG pathway analysis. These genes not only bind to H3K4me3, ERα and Flag-Brca1, but also have increased expression in MTP12 (as shown in Figure 2A). The data showed that five well-known oncogenic pathways, including the cancer pathways PI3K-AKT, Ras, MAPK and Rap1, were among the top 10 enriched pathways (as shown in Figure 7A). Further analysis identified 50 top candidate genes, including Shcbp1 and several other genes that were highly activated in MTP12 breast (as shown in Figure 7B). Since Shcbp1 is considered to be one of the four hallmark genes that predict breast cancer survival, metastasis and drug response, this example chose to focus on SHCBP1. Consistent with previous studies, in P12 Brca1-MT mice, an increase in H3K4me3 binding peaks was observed in the promoter region (as shown in Figure 7C). ChIP-qPCR results showed that compared with the IgG control group, the binding of Smyd3 to the Shcbp1 promoter was enriched by more than 5 times in Brca1-MT-G600 cells (as shown in Figure 7D), indicating that Smyd3 can directly regulate the expression of Shcbp1. Consistent with previous analyses, this example also detected a positive correlation between the expression of Smyd3 and Shcbp1 in precancerous tissues and tumor tissues (as shown in Figures 3F and 7E), indicating that Smyd3 is a universal regulatory factor for Shcbp1.

[0155] To investigate whether Smyd3 could enhance the oncogenic effects of Shcbp1, we first verified the expression of Shcbp1 and its downstream genes, Kras, Src, Sos1, and Grb2. We found that these genes were elevated in mammary tissue from MT P12 mice and in Brca1-MT mammary tumors compared to controls (Figures 8A-C). To further investigate this, we performed functional analyses in this example by introducing sgSmyd3 or sgSmyd3 / OE-Smyd3 into WT-B477 and MT-G600 cells to detect Shcbp1 expression (Figures 8D and G). The data in Figures 8E-F and 1H show that in both cell lines, sgSmyd3-containing cells reduced the expression of Shcbp1 and the Shcbp1 downstream genes, Kras, Src, Sos1, and Grb2, as well as the expression of the Smyd3 downstream genes, Psmd9 and Psen2. In contrast, when Smyd3 cDNA was introduced into both G600 (Figures 8E-F) and B477 (Figures 8H-I) cells expressing sgSmyd3, the reduced gene expression was restored. These data suggest that Smyd3 can positively induce the increased expression of Shcbp1 and Kras-MAPK signaling, sustaining their expression and promoting breast tumor progression.

[0156] To investigate whether aberrant transcriptional regulation of Smyd3 affects the protein levels of Shcbp1 and Kras-MAPK signaling, this example overexpressed (OE) Smyd3 in WT-B477 cells and knocked out the Smyd3 gene in Brca1-MT-G600 cells using two different sgRNAs targeting Smyd3. The results showed that compared with the control group, Shcbp1, Kras, and pMek protein levels were increased in WT-B477 cells expressing OE-Smyd3 (as shown in Figure 7G), while Shcbp1, Kras, and pMek protein levels were decreased in Brca1-MT-G600 cells expressing sgSmyd3 (as shown in Figure 7H). Consistent with the functional analysis, the protein levels of Shcbp1, Kras, and pErk decreased in G600 cells treated with the Smyd3 inhibitor BCI-121 (as shown in Figure 7I), indicating that Smyd3 acts at the upstream level of the Shcbp1 and Kras-MAPK oncogenic pathway. To explore whether Smyd3 can regulate Kras-MAPK through Shcbp1, this example expressed sgSmyd3 in Brca1-MT-545 cells and then overexpressed OE-Shcbp1 in the same cells. The results showed that the protein levels of Kras and pErk increased (as shown in Figure 7J). Using the same strategy, SMYD3 was first overexpressed in MDA-MB-231 and HCC1937 cells, followed by knockdown of SHCBP1. Reduced SHCBP1 and KRAS-MAPK oncogenic signals were detected in both cell lines (as shown in Figures 7K-L). Further studies showed that overexpression of OE-Brca1 cDNA could inhibit the oncogenic signaling of Shcbp1-Kras-MAPK (as shown in Figure 7M), which is consistent with the view that the oncogenic effect of Smyd3 caused by Brca1 loss in mammary epithelial cells may be mediated by Shcbp1.

[0157] Example 5

[0158] This example demonstrates that silencing SMYD3 or SHCBP1 can weaken the oncogenic effect of the Kras-MAPK pathway and inhibit breast tumor growth.

[0159] These studies demonstrate that elevated Smyd3 acts as an upstream factor of Shcbp1. This study investigated whether the Smyd3 inhibitor BCI-121 50 could inhibit its carcinogenic effects. However, data showed that BCI-121 had minimal inhibitory effect on the growth of G600 and MDA-MB-231 tumors implanted in mice. This observation suggests that BCI-121 either fails to inhibit Smyd3 signaling or, for unknown reasons, fails to enter cancer cells. To monitor the potential efficacy of the drug, this study used an in vivo slice culture platform to culture these tumor samples. In this experiment, freshly dissected tumor tissues were sliced, cultured in 24-well plates, and treated with BCI-121 for 7 days. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays revealed a significant increase in cell death after BCI-121 treatment compared to controls (Figures 9A-B and 10A-B). Immunohistochemical staining with antibodies to Smyd3, H3K4me3, and Ki67 then showed that the protein levels of Smyd3, H3K4me3, and Ki67 were significantly reduced in tumor sections treated with BCI-121 (as shown in Figures 9C-D and 10C-D), indicating that inhibition of Smyd3 can abolish the oncogenic effects of downstream genes enhanced by Smyd3 and ERα.

[0160] To further investigate whether the inhibitory effect is truly due to the inhibition of Smyd3 or Shcbp1, this example implanted G600 cells expressing sgSmyd3 or sgShcbp1 into the fat pad of nude mice and monitored tumor growth. The data showed that knocking out Smyd3 or Shcbp1 in these cells did not affect cell growth in vitro (as shown in Figure 9E), but significantly hindered tumor growth (as shown in Figures 9F-I) and reversed splenomegaly (as shown in Figures 10E-F). Consistent with this, compared with the parental control group, the protein levels of Shcbp1, Kras, and pMek were significantly reduced in tumor tissues expressing sgSmyd3 or sgShcbp1 (as shown in Figures 9J-K), indicating that Smyd3 and Shcbp1 are major oncogenic drivers. Silencing Smyd3 and Shcbp1 in mammary epithelial cells can not only maximally inhibit tumor cell growth, but also block their negative effects on abnormal immune responses in spleen tissue.

[0161] Further experiments were conducted in mice with normal immune systems using the 545 cell line, which is derived from Brca1-MT mouse mammary tumors and can be grown in FVB mice. It was observed that knocking out either sgSmyd3 or sgShcbp1 had similar anti-cancer effects (as shown in Figure 10G-H).

[0162] In this example, human cell lines MDA-MB-231 and HCC1937 expressing sgSMYD3 or sgSHCBP1 were orthotopically implanted into the fat pads of nude mice and tumor growth was monitored. Similarly, knocking out SMYD3 or SHCBP1 in these cells did not affect cell growth in vitro, but significantly inhibited tumor growth and reversed the splenomegaly phenotype (Figures 9L-O and 10I-K). In tumor tissues expressing sgSMYD3, protein levels of SMYD3, SHCBP1, KRAS, and pMEK were decreased compared to the parental control group, consistent with the significant anticancer effect of sgSMYD3 (as shown in Figure 9P). In tumor tissues expressing sgSHCBP1, levels of SHCBP1, KRAS, GRB2, and pERK were also significantly reduced compared to the parental control group (as shown in Figure 9Q). These data indicate that when the functions of SMYD3 and SHCBP1 are disrupted, breast tumor progression can be significantly inhibited.

[0163] Example 6

[0164] This example demonstrates that elevated Smyd3 and Shcbp1 create an immunosuppressive microenvironment in breast tumor tissue.

[0165] The tumor immunosuppressive microenvironment (TIME) plays a crucial role in supporting tumor growth and metastasis, but the impact of SMYD3 and SHCBP1 on the TME remains unclear. Since inhibition of Smyd3 or Shcbp1 significantly reduces tumor growth in both allograft and xenograft models, it was hypothesized that elevated Smyd3 or Shcbp1 could shape TIME in mammary tissue, thereby favoring the growth of malignant mammary epithelial cells. To test this hypothesis, this example used the HP5712 (HP) cell line, which is derived from the mammary glands of FVB mice with an intact immune system and high expression of Smyd3 and Shcbp1 (as shown in Figure 11A). HP cell lines overexpressing Smyd3, sgSmyd3, and OE-Smyd3 / sgShcbp1 were then established (as shown in Figure 11B).

[0166] Data in Figures 11C-E and 12A show that compared to HP parental cells, tumor growth was faster after implantation of HP-OE-Smyd3, while tumor growth was significantly reduced after implantation of HP-sgSmyd3 or OE-Smyd3 / sgShcbp1, with associated protein levels increased and decreased, respectively. Figures 11F and 12B-C show that, consistent with the tumor growth phenotype, mice implanted with OE-Smyd3 had enhanced splenomegaly compared to mice implanted with parental cells, while mice implanted with HP-sgSmyd3 or HP-OE-Smyd3 / sgShcbp1 had a reversed splenomegaly phenotype, but no obvious abnormal phenotype was observed in the liver, suggesting that elevated Smyd3 or Shcbp1 expression can trigger behavioral changes in immune cells in breast tumors.

[0167] Furthermore, this example detected immune cell populations in the mammary glands of WT FVB mice and tumor-bearing mice implanted with parental HP cells, HP-OE-Smyd3, HP-OE-Smyd3 / sgShcbp1, or sgSmyd3, respectively. MDSCs were analyzed by CyTOF using Cd3, Cd4, Cd11b, Ly6G, and Ly6C antibodies, M1-like macrophages were detected using F4 / 80 and Cd86 antibodies, and M2-like macrophages were detected using F4 / 80 and Cd206 antibodies.

[0168] The data in Figures 11G-M and 12D-G showed that compared with the mammary tissue of control FVB mice, the number of effector cells, including Cd4+, Cd8+ cells and M1-like macrophages, in FVB mice implanted with HP parental cells and HP-OE-Smyd3 cells was significantly reduced, while the corresponding effector cell numbers in FVB mice implanted with HP-OE-Smyd3 / sgShcbp1 or HP-sgSmyd3 cells were significantly increased. In contrast, protective cell populations, including M-MDSCs (mononuclear MDSCs) double-positive for Cd11b and Ly6C antibodies and PMN-MDSCs (polymorphonuclear myeloid-derived suppressor cells) double-positive for Cd11b and Ly6G antibodies, as well as M2-like macrophage populations double-positive for F4 / 80 and Cd206 antibodies, were significantly increased in FVB mice implanted with HP parental cells and HP-OE-Smyd3 cells compared with WT FVB mammary tissue, indicating that the increased expression of Smyd3 and Shcbp1 reprograms the normal microenvironment into TIME, and these changes can be reversed by blocking their expression.

[0169] To investigate whether the differential expression of Smyd3 and Shcbp1 affects T cell function, the mammary tissues of WT FVB mice and FVB mice implanted with HP-OE-Smyd3, HP-OE-sgSmyd3, and HP-OE-Smyd3 / sgShcbp1 cells were stained with PD1 and CD3 antibodies combined with IF, and the T lymphocyte status in mammary tissues and breast tumor lymph nodes was detected.

[0170] Figure 11N and OR data show that the number of PD1 and CD3 double-positive T cells in FVB mice implanted with HP-OE-Smyd3 cells (98%) was significantly higher than that in WT mice (8.75%), sgSmyd3 (4.3%), or mice expressing both OE-Smyd3 and sgShcbp1 (3.53%). These results suggest that the tumorigenic signaling induced by Smyd3 and Shcbp1 can reduce the number of effector cells, destroy immune cells, and support tumor growth.

[0171] To further investigate whether the oncogenic effects of Smyd3 and Shcbp1 can regulate the expression of PD-L1 in epithelial cells through transcriptional regulation and be associated with changes in the state of immune cells, this example detected the expression levels of PD-L1 in the HP cell line and PD1 in the spleen tissue of FVB mice in the control group and the OE-Smyd3, sgSmyd3, and OE-Smyd3 / sgShcbp1 groups.

[0172] Figure 11S-W data show that PD-L1 expression is significantly reduced in cells expressing sgSmyd3 or OE-Smyd3 / sgShcbp1. In contrast, PD1 expression is elevated in mice expressing OE-Smyd3 HP parental cells, whereas PD1 expression is reduced in HP cells expressing sgSmyd3 or OE-Smyd3 / sgShcbp1. Oncogenic expression of Smyd3 and Shcbp1 can affect PD-L1 transcription in epithelial cells and alter the status of effector T cells in tumors. Consistent with studies in mice, TCGA data analysis also showed that SMYD3 expression is negatively correlated with the abundance of activated CD4 and CD8, while SHCBP1 expression is positively correlated with the number of MDSCs.

[0173] Example 7

[0174] This example demonstrates that combined therapy with trametinib and PD1 antibody can reverse Smyd3 expression and sensitize tumors to ICB.

[0175] The above data demonstrate that sgSmyd3 and sgShcbp1 effectively inhibit the oncogenic transformation of precancerous cells. Therefore, the inventors sought a drug that could inhibit elevated Smyd3-Shcbp1 signaling. Since trametinib is a MEK inhibitor and has been approved by the FDA as an anticancer drug for melanoma, this example experimentally verified whether trametinib affects breast tumor formation in mice.

[0176] G600 cells were first implanted into the fat pads of nude mice. One week later, the mice were treated with trametinib every other day. Data in Figures 14A-F show that trametinib treatment significantly retarded tumor growth and reversed the splenomegaly phenotype, but no significant changes were observed in the spleen or liver. This finding is further supported by decreased protein levels of pMek, pErk, Kras, and Grb2 in treated tumors with impaired Kras-MAPK oncogenic pathways compared to untreated tumors, indicating that trametinib has a significant inhibitory effect in breast tumors with elevated Smyd3-Shcbp1 signaling.

[0177] As shown in Figure 11N, the increase of Smyd3 increases the number of PD1 and CD3 double-positive cells. Therefore, this example explores the effects of single-drug and dual-drug treatment with trametinib and PD1 antibody in FVB tumor-bearing mice, and implants the HP5712 cell line derived from spontaneous mammary tumors in FVB mice.

[0178] The data in Figures 13A-D and 14G show that PD1 antibody treatment had no significant effect compared to the parental control, indicating that breast tumors with elevated Smyd3 and Shcbp1 levels are resistant to PD1 antibody treatment, while trametinib can reduce tumor progression. However, combined treatment with PD1 antibody and trametinib produced a stronger effect on tumor weight and tumor volume, and reversed the splenomegaly phenotype.

[0179] To verify this idea, CyTOF analysis showed that M-MDSCs and PMN-MDSCs began to decrease from day 12 and continued to decrease until day 22 (as shown in Figures 13E, G, and 14H), while CD4+ and CD8+ cells began to increase in the trametinib-treated group (as shown in Figures 13F, H, and 14H), and the effect was enhanced in the dual-drug treatment group. The results indicate that blocking oncogenic pathways with trametinib can significantly sensitize immune cell populations and sensitize tumors to PD1 antibody treatment by reducing stimulation from malignant epithelial cells and blocking PD1 and PD-L1 interactions between malignant epithelial cells and immune cells caused by elevated Smyd3 and Shcbp1 signaling. As shown in Figures 13I-J and 14I-J, the protein and mRNA levels of Smyd3 and Shcbp1 began to decrease on day 12 in both the trametinib monotherapy group and the trametinib plus PD1 antibody dual-drug group, with the effect being much stronger on day 22. However, there was no significant decrease in protein levels in the PD1 antibody monotherapy group on days 12 and 22. This suggests that trametinib treatment can reverse the expression of Smyd3 and Shcbp1 and could be a promising treatment for breast cancer patients with elevated Smyd3-Shcbp1 signaling levels.

[0180] Consistent with the above results, on day 12 (Figure 7K) and day 22 (Figure 7L), the levels of pMek, pErk, Kras, and Grb2 proteins were also significantly reduced in the trametinib monotherapy and dual-drug groups, with no obvious toxicity in the liver and spleen (as shown in Figures 13K-L and 14M-N).

[0181] Furthermore, this example demonstrates whether treatment with this drug can reverse estrogen (E2)-induced Smyd3 / Shcbp1 expression in G600 and HP cell lines. As shown in Figures 13M-N and 14K-L, E2 simultaneously induced the expression of Smyd3 and Shcbp1 at multiple time points. After 24 hours, the expression of both genes was suppressed by trametinib in both the groups receiving trametinib alone and the combination of E2 and trametinib. This demonstrates that trametinib can indeed reverse the oncogenic expression of Smyd3 and Shcbp1 in mammary epithelial cells and could serve as a potential therapeutic for breast cancer patients.

[0182] In summary, the combination of trametinib and PD-1 antibody can sensitize breast tumors containing high levels of Smyd3 and Shcbp1 to ICB by reversing the tumorigenic expression of Smyd3 and Shcbp1 in breast epithelial cells and increasing the functional T cell population.

[0183] The foregoing description is merely a preferred embodiment of the present disclosure and is not intended to limit the present disclosure. Those skilled in the art will readily appreciate that the present disclosure is susceptible to various modifications and variations. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present disclosure shall be included within the scope of protection of the present disclosure. Industrial Applicability

[0184] The present disclosure provides the use of a SMYD3-SHCBP1 inhibitor in combination with a PD1 inhibitor in the preparation of a drug for treating cancer. The present disclosure experimentally identifies Smyd3-Shcbp1 as the initial oncogenic signal in precancerous mammary epithelial cells that mediates the tumorigenic effects of Brca1 and ERα during pregnancy, before tumor development, and during tumor development. It also demonstrates that elevated Smyd3-Shcbp1 signaling can reprogram the tumor immunosuppressive microenvironment, leading to immunotherapy resistance after PD1 antibody treatment. Treatment with trametinib reverses SMYD3-SHCBP1 expression, and combined trametinib and PD1 antibody therapy enhances effector T cell function, making breast tumors with elevated SMYD3 and SHCBP1 sensitive to ICBs, demonstrating excellent industrial applicability.

Claims

1. Use of a SMYD3 inhibitor and / or a SHCBP1 inhibitor in the preparation of a medicament for preventing or treating cancer.

2. The use according to claim 1, characterized in that: The cancer is a solid tumor; optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the solid tumor is a cancer selected from the group consisting of breast cancer, melanoma, lung cancer or liver cancer.

3. The use according to claim 1 or 2, characterized in that: The SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor inhibits the expression of Smyd3 or Shcbp1, thereby inhibiting the abnormal activation of SMYD3 / SHCBP1 and its downstream signaling pathways in cancer and the formation of a tumor immunosuppressive microenvironment.

4. Use of SMYD3 inhibitors and / or SHCBP1 inhibitors in the preparation of drugs for reducing drug resistance of cancer cells; Optionally, the cancer cell is a tumor cell or cancer cell that is insensitive to PD1 antibody treatment; Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

5. The use according to claim 4, characterized in that: The SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib.

6. Use of a SMYD3 inhibitor and / or a SHCBP1 inhibitor in combination with a PD1 inhibitor in the preparation of a drug for preventing or treating cancer.

7. The use according to claim 6, characterized in that: The cancer is a solid tumor; Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the solid tumor is a cancer selected from the group consisting of breast cancer, melanoma, lung cancer or liver cancer.

8. The use according to claim 6 or 7, characterized in that: The SMYD3 inhibitor and / or SHCBP1 inhibitor includes any one or more of trametinib, BAY-6035 or BCI-121; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor is trametinib.

9. The use according to any one of claims 6 to 8, characterized in that: The PD1 inhibitor is an anti-PD1 antibody; Optionally, the anti-PD1 antibody is selected from at least one of the following groups: Nivolumab, Pembrolizumab, Pidilizumab, Lambrolizumab, BMS-936559, Atezolizumab, AMP-224, AMP224, AUNP12, BGB108, MCLA134, MEDI0680, PDROOl, REGN2810, SHR1210, STIA110X, STIA1110, TSR042, BMS-936558, BGB-A317, BCD-100 and JS001.

10. A drug or a pharmaceutical composition, characterized in that The active ingredients of the drug include: SMYD3 inhibitor and / or SHCBP1 inhibitor; Optionally, the active ingredients of the drug further include: PD-1 inhibitor; Optionally, the drug further comprises pharmaceutically acceptable excipients.

11. A method for preventing or treating a tumor, comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or a SHCBP1 inhibitor to a subject in need thereof; Optionally, the tumor is a solid tumor; Optionally, the solid tumor is a benign tumor or a malignant tumor; Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the benign tumor is a breast tumor.

12. A method for inhibiting, reversing or reducing the drug resistance of drug-resistant cancer cells, the method comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or a SHCBP1 inhibitor to a subject in need thereof; Optionally, the cancer cell is a tumor cell or cancer cell that is insensitive to PD1 antibody treatment; Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

13. A method for preventing or treating tumors, comprising administering a therapeutically effective amount of a SMYD3 inhibitor and / or a SHCBP1 inhibitor and a PD1 inhibitor to a subject in need thereof; Optionally, the tumor is a solid tumor; Optionally, the solid tumor is a benign tumor or a malignant tumor; Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor and PD1 inhibitor are administered concurrently or sequentially; Optionally, the benign tumor is a breast tumor.

14. A SMYD3 inhibitor and / or a SHCBP1 inhibitor for use in preventing or treating tumors; Optionally, the tumor is a solid tumor; Optionally, the solid tumor is a benign tumor or a malignant tumor; Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the SMYD3 inhibitor and / or SHCBP1 inhibitor and PD1 inhibitor are administered concurrently or sequentially; optionally, the benign tumor is a breast tumor.

15. A SMYD3 inhibitor and / or SHCBP1 inhibitor for inhibiting, reversing or reducing the drug resistance of drug-resistant cancer cells; Optionally, the cancer cell is a tumor cell or cancer cell that is insensitive to PD1 antibody treatment; Optionally, the cancer cells are breast tumor cells or breast cancer cells that are insensitive to PD1 antibody treatment.

16. A SMYD3 inhibitor and / or SHCBP1 inhibitor combined with a PD1 inhibitor for preventing or treating tumors; Optionally, the tumor is a solid tumor; Optionally, the solid tumor is a benign tumor or a malignant tumor; Optionally, the solid tumor is a solid tumor that is insensitive to PD1 antibody treatment; Optionally, the benign tumor is a breast tumor.

Citation Information

Patent Citations

  • Application of trametinib in preparing medicine for reversing multi-medicine resistance of tumors

    CN104434924A

  • Application of FGFR and related signal pathway inhibitor thereof in preparation of medicine for treating FGFR2 mutant tumors

    CN113730587A

  • Application of BCI-121 or pharmaceutically acceptable salt thereof in preparation of medicine for preventing or treating gastric cancer

    CN115990163A